Dishman Carbogen Amcis jumped 6.81% to Rs 127.90 after the company said that its board will consider fund raising through issuance of non-convertible debentures (NCDs) on Friday, 10 March 2023.
The pharma company said that the NCDs will be issued by way of private placement, subject to such regulatory or statutory approvals as may be required.Dishman Carbogen Amcis is a fully integrated CRAMS (contract research & manufacturing) company. The company has global presence with development and manufacturing sites in Switzerland, UK, France, Netherlands, India, and China.
The company's consolidated net profit rose 32.7% to Rs 46.96 crore on 13.8% increase in revenue from operations to Rs 639.79 crore in Q3 December 2022 over Q3 December 2021.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app